Q-omics provides the consensus-scored MT1HL1 profile across patient tissues and cancer cell-line models. MT1HL1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MT1HL1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MT1HL1 RNA expression shows 7,088 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, KIRC, and TGCT as cancer lineages where MT1HL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1HL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1HL1 survival associations across molecular data types. MT1HL1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1HL1 RNA expression–survival associations across cancer types. High MT1HL1 expression shows unfavorable associations in CHOL, HNSC, BLCA, ACC and COAD, but favorable associations in STAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MT1HL1 RNA expression.
This table summarizes MT1HL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MT1HL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1HL1 shows lower tumor expression in KIRC, KICH, KIRP, LIHC and THCA and higher tumor expression in HNSC. The KIRC box plot shows higher MT1HL1 RNA expression in normal versus tumor tissue (log2 FC = −0.504, t-test p < 0.001).
This table shows molecular features associated with MT1HL1 in patient tissues and cancer cell lines. In patient samples, MT1HL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1HL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
